Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
June 3, 2026
Communiqué de presse : Sanofi fédère l'écosystème de santé pour accélérer le diagnostic des maladies rares en France : Biogen rejoint accelRare
May 28, 2026
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
May 18, 2026
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Upcoming Events
2Jun
2026
BNP Paribas Exane CEO conference l Paris
Speaker – François Roger, Executive Vice President, Chief Financial Officer
Conferences
3Jun
2026
11Jun
2026
Citi European Healthcare CEO Conference l London
Conferences
31st Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00